Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD - Result

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Research output: Contribution to journal › Journal article › Research › peer-review

Documents

Single-inhaler triple therapy fluticasone furoate
Final published version, 800 KB, PDF document

Nicola C. Day
Subramanya Kumar
Gerard Criner
Mark Dransfield
David M. G. Halpin
MeiLan K. Han
C. Elaine Jones
Morrys C. Kaisermann
Sally Kilbride
Lange, Peter
David A. Lomas
Neil Martin
Fernando J. Martinez
Dave Singh
Robert Wise
David A. Lipson

Original language	English
Journal	Respiratory research
Volume	21
Number of pages	12
ISSN	1465-9921
DOIs	https://doi.org/10.1186/s12931-020-01398-w
Publication status	Published - 2020

Research areas

COPD, Triple therapy, LAMA/LABA, ICS/LABA, Cardiovascular safety

Number of downloads are based on statistics from Google Scholar and www.ku.dk

No data available

ID: 243905687